biostudies-literatureViet CTNIDCR NIH HHSOral and Maxillofacial Surgery Foundation42https://www.ebi.ac.uk/biostudies/studies/S-EPMC8178935biostudies-literatureUnknown9(1)<h4>Background</h4>Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction. In this study we focused on early-stage (I/II) OSCC and created a risk score called the REASON score, which combines clinicopathologic characteristics with a 12-gene methylation signature, to predict the risk of 5-year mortality.<h4>Methods<Biomarker researchThe REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma.PMC8178935K23 DE030250McGue CMAsam KCheng ACViet CTCouey MAThomas CMDoan CYu GKilkuts CALee SCGrandhi AAouizerat BECallahan NFNguyen KWongworawat YCPhilipone EWalker PCYoon AJPatel AAKidd SCAllen CTRicks OLHaghighiabyaneh MfalseThe REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma.<h4>Background</h4>Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction. In this study we focused on early-stage (I/II) OSCC and created a risk score called the REASON score, which combines clinicopathologic characteristics with a 12-gene methylation signature, to predict the risk of 5-year mortality.<h4>Methods<2021-01-01T00:00:00Z2021 Jun2025-04-26T15:35:54.143Z2022-02-10T14:06:36.2ZS-EPMC81789353409051810.1186/s40364-021-00292-x